Our top pick for
Building a portfolio
Personalis, Inc is a diagnostics & research business based in the US. Personalis shares (PSNL) are listed on the NASDAQ and all prices are listed in US Dollars. Personalis employs 234 staff and has a trailing 12-month revenue of around USD$78.6 million.
|52-week range||USD$7.8739 - USD$53.46|
|50-day moving average||USD$27.1832|
|200-day moving average||USD$31.3951|
|Wall St. target price||USD$42|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.736|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Personalis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Personalis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Personalis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Personalis shares trade at around 54x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$78.6 million|
|Gross profit TTM||USD$20.1 million|
|Return on assets TTM||-13.1%|
|Return on equity TTM||-27.37%|
|Market capitalisation||USD$1 billion|
TTM: trailing 12 months
There are currently 3.1 million Personalis shares held short by investors – that's known as Personalis's "short interest". This figure is 34% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Personalis shares can be evaluated.
Personalis's "short interest ratio" (SIR) is the quantity of Personalis shares currently shorted divided by the average quantity of Personalis shares traded daily (recently around 1.2 million). Personalis's SIR currently stands at 2.66. In other words for every 100,000 Personalis shares traded daily on the market, roughly 2660 shares are currently held short.
However Personalis's short interest can also be evaluated against the total number of Personalis shares, or, against the total number of tradable Personalis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Personalis's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Personalis shares in existence, roughly 70 shares are currently held short) or 0.0974% of the tradable shares (for every 100,000 tradable Personalis shares, roughly 97 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Personalis.
Find out more about how you can short Personalis stock.
We're not expecting Personalis to pay a dividend over the next 12 months.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.